Neuropharmacology & Neurotherapeutics
Natalizumab
Mar. 01, 2021
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.
One month after initial presentation, there is irregularity of multiple intracranial branches including the distal internal carotid arteries, distal vertebral arteries, basilar artery, and proximal segments of the anterior, middle, and posterior cerebral arteries bilaterally. The noted irregularities have improved since the initial examination. CT angiogram findings were consistent with improvement of the intracranial vasculopathy. Our clinical impression was that our patient had possible PRES as well as reversible segmental cerebral vasoconstriction (Call-Fleming syndrome), possibly due to treatment with cyclosporine. Tacrolimus neurotoxicity has also been associated with PRES. (Contributed by Dr. Jose Biller.)